ArticleAnnals of transplantation2019
Effect of Calculated Panel Reactive Antibody Value on Waitlist Outcomes for Lung Transplant Candidates.
Article in Annals of transplantation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Long-Term Chronic Lung Allograft Dysfunction-Free Survival Following Lung Transplant in the Presence of Donor-Specific Antibodies.Clinical transplantation · 2025Article
- Intraoperative Plasma Exchange for Sensitized Lung Transplantation Candidate Leads to Significant Perioperative Coagulopathy.Annals of cardiac anaesthesia · 2025Article
- Accessing the Impacts of the Calculated Panel Reactive Antibody Value on a Lung Transplant Waitlist: A Latin American Experience.Journal of clinical medicine · 2025Article
- Increased delay to lung transplantation for women candidates: gender-based disparity matters in the lung transplant trajectory.ERJ open research · 2025Article
- Antibody-Mediated Rejection in Lung Transplantation: Diagnosis and Therapeutic Armamentarium in a 21st Century Perspective.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Immunological considerations-HLA matching and management of high immunological risk recipients.Indian journal of thoracic and cardiovascular surgery · 2022Review
- Approaching the sensitized lung patient: risk assessment for donor acceptance.Journal of thoracic disease · 2021Review
- Lung transplant waitlist outcomes in the United States and patient travel distance.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- The fraction of sensitization among lung transplant recipients in a transplant center in Japan.BMC pulmonary medicine · 2020Article
- Perspectives on donor lung allocation from both sides of the Atlantic: The United States.Clinical transplantation · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND We conducted a retrospective cohort study using United Network of Organ Sharing (UNOS) data to determine the effect of the calculated panel reactive antibody (cPRA) value on waitlist outcomes for lung transplant candidates. MATERIAL AND METHODS We divided lung transplant candidates into groups based on their cPRA value at the time of waitlist activation (0-25%, 25.1-50%, 50.1-75%, and 75.1-100%) and compared each group's waitlist outcomes to the lowest quartile ("minimally sensitized") group. The primary outcome was lung transplantation and the secondary outcome was waitlist mortality (a composite of death on the waitlist/delisting for clinical deterioration). RESULTS Compared to the minimally sensitized group, candidates with a cPRA value of 25.1-50% did not have a significantly different likelihood of undergoing lung transplant or waitlist mortality, candidates with a cPRA value of 50.1-75% were 25% less likely to undergo lung transplant and 44% more likely to die on the waitlist, and candidates with a cPRA value of 75.1-100% were 52% less likely to undergo lung transplant and 92% more likely to die on the waitlist. CONCLUSIONS CPRA values of greater than 50% are associated with significantly lower rates of transplantation and higher waitlist mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.